Guo Congfang, Zhao Hua, Wang Yu, Bai Shuai, Yang Zizhong, Wei Feng, Ren Xiubao
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
National Clinical Research Center for Cancer, Tianjin, China.
Front Oncol. 2019 May 28;9:439. doi: 10.3389/fonc.2019.00439. eCollection 2019.
This study evaluated the prognostic value of the newly-built Immunoscore (neo-Immunoscore) in patients with renal cell carcinoma (RCC). Eighty-two patients with RCC were enrolled in this study. Their 3- and 5-year survival rates and overall survival (OS) were evaluated. The clinicopathologic data of the 82 patients were collected and analyzed. CD3, CD4, CD8, CD45RO, Foxp3, tumor necrosis factor receptor type II (TNFR2), programmed death ligand-1 (PD-L1), CD68, programmed death-1 (PD-1), cytokeratin (CK), and indoleamine 2,3-dioxygenase (IDO) were separated into two panels and stained using multiplex fluorescent immunohistochemistry methods. An immunologic prediction model of RCC patients, the neo-Immunoscore (neo-IS), was constructed using a Cox regression model. For the prognostic prediction of RCC, the neo-IS with the immunoscore (IS) proposed by the Society for Immunotherapy of Cancer (SITC) were compared by receiver operator characteristic (ROC) curve analysis. Survivals between the neo-IS and neo-IS groups were analyzed using the Kaplan-Meier method. Multivariate Cox regression survival analysis was applied to analyze independent indicators. The Cox regression model allowed the establishment of a neo-IS based on three features: CD , CD4Foxp3CD45RO , and CD8PD- . Compared to that of the IS proposed by the SITC, the neo-IS obtained a better prediction. The 3- and 5-year survival rates in neo-IS RCC patients were significantly higher than those in neo-IS RCC patients (94.7 vs. 77.4%, = 0.035 and 94.7 vs. 64.5%, = 0.002, respectively). The OS in the neo-IS group was significantly shorter than that in the neo-IS group (73 vs. 97 months, = 0.000). In comparisons of the neo-IS with clinical pathological factors, we found that the risk stratification and neo-IS were independent factors for the prognosis of patients with RCC. Moreover, the OS rate of neo-IS RCC patients with low- and intermediate- risk was higher than that of neo-IS patients. The newly-constructed IS model more precisely predicted the survival of patients with RCC and may supplement the prognostic value of risk stratification.
本研究评估了新建的免疫评分(neo-免疫评分)在肾细胞癌(RCC)患者中的预后价值。本研究纳入了82例RCC患者。评估了他们的3年和5年生存率以及总生存期(OS)。收集并分析了这82例患者的临床病理数据。将CD3、CD4、CD8、CD45RO、Foxp3、肿瘤坏死因子受体II型(TNFR2)、程序性死亡配体-1(PD-L1)、CD68、程序性死亡-1(PD-1)、细胞角蛋白(CK)和吲哚胺2,3-双加氧酶(IDO)分为两个面板,并采用多重荧光免疫组织化学方法进行染色。使用Cox回归模型构建了RCC患者的免疫预测模型,即neo-免疫评分(neo-IS)。为了对RCC进行预后预测,通过受试者工作特征(ROC)曲线分析比较了neo-IS与癌症免疫治疗协会(SITC)提出的免疫评分(IS)。使用Kaplan-Meier方法分析了neo-IS组和neo-IS组之间的生存率。应用多变量Cox回归生存分析来分析独立指标。Cox回归模型基于三个特征建立了neo-IS:CD 、CD4Foxp3CD45RO 、以及CD8PD- 。与SITC提出的IS相比,neo-IS获得了更好的预测效果。neo-IS RCC患者的3年和5年生存率显著高于neo-IS RCC患者(分别为94.7%对77.4%,P = 0.035;以及94.7%对64.5%,P = 0.002)。neo-IS组的OS显著短于neo-IS组(73个月对97个月,P = 0.000)。在neo-IS与临床病理因素的比较中,我们发现风险分层和neo-IS是RCC患者预后的独立因素。此外,低风险和中风险的neo-IS RCC患者的OS率高于neo-IS患者。新构建的IS模型更精确地预测了RCC患者的生存情况,可能补充风险分层的预后价值。